333361-51-6

Basic information

• Product Name: 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene
• Synonyms: 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene
• CAS NO: 333361-51-6
• Molecular Formula: C14H12BrClO
• Molecular Weight: 311.60148
• Mol File: 333361-51-6.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 379.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.410±0.06 g/cm3(Predicted)
• Solubility: Dichloromethane; Ethyl Acetate
• CAS DataBase Reference: 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene(333361-51-6)
• EPA Substance Registry System: 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene(333361-51-6)

Safety Data

• Hazardous Substances Data: 333361-51-6(Hazardous Substances Data)

Usage

Description

4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene is an organic compound that serves as a key intermediate in the synthesis of pharmaceuticals. It is characterized by the presence of a bromo, chloro, and methoxy-benzyl functional groups attached to a benzene ring, which contribute to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene is used as a chemical intermediate for the synthesis of Dapagliflozin-D5 (D185372), a labelled analogue of Dapagliflozin (D185370). Dapagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, making it an effective treatment for patients with type 2 diabetes. 4-Bromo-1-chloro-2-(4-methoxy-benzyl)-benzene plays a crucial role in the development of this medication, facilitating its production and enhancing its therapeutic potential.

Upstream product

• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 333361-49-2 (5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone 

Downstream Products

• 461432-26-8 dapagliflozin 
• 864070-19-9 [4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane 
• 1204220-63-2 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1204220-65-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-80-6 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(ethoxy-d5)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-68-0 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(ethoxy-1,1-d2)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-27-1 (2R,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 333359-90-3 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-methoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-88-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(methoxy-d3)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 912917-83-0 (3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 

Relevant articles and documents

GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS

The present invention is directed to glucopyranose derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Synthetic method for empagliflozin related substance IMPD

The invention discloses a synthetic method for empagliflozin related substance IMPD. In a current synthetic method of IMPD, a whole synthetic route is longer and the total yield is lower. The synthetic method provided by the invention comprises the following steps: performing hydroxylation by using (2-chloro-5-iodophenyl)(4-fluorophenyl)methanone as a raw material to obtain (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone, performing a reaction by using a carbonyl reducing agent to obtain 4-(5-iodo-2-chlorobenzyl)phenol, protecting phenolic hydroxyl groups by using protecting groups such as TBDMS, performing metallization of aromatic iodide by adopting a relatively stable and safe Grignard reagent i-PrMgCl.LiCl, performing methyl glucoside reduction by using a Lewis acid catalyst, and finally performing quenching to obtain the empagliflozin related substance IMPD. The synthetic method provided by the invention has the advantages of an abundant raw material source, a simple, quick andhigh-efficiency reaction, milder reaction conditions, a higher total yield and low costs.

Carbon glucoside sodium glucose transport protein body 2 inhibitor

The invention relates to a carbon glucoside sodium glucose transport protein body 2 inhibitor, a preparation method and an application of the inhibitor. The carbon glucoside sodium glucose transport protein body 2 inhibitor has a structure as shown in general formula (I) as shown in the specification.